Peptide Therapeutics CDMO Market Revenue and Forecast by 2033

17 Sep 2025

Share :

Table of Content

1. Peptide Therapeutics CDMO Market Revenue and Trends 2025 to 2033 2. Key Drivers Enabling the Growth of the Peptide Therapeutics CDMO Market 3. Segment Insights 4. Regional Insights 5. Peptide Therapeutics CDMO  Market Coverage

Peptide Therapeutics CDMO Market Revenue and Trends 2025 to 2033

The global peptide therapeutics CDMO market is expanding rapidly due to rising demand for complex peptide drug manufacturing services. The peptide therapeutics CDMO market comprises companies that offer specialized services for the research, development, and production of peptide-based drugs. This market is driven by the growing need for effective treatments for chronic conditions such as cancer, diabetes, and metabolic disorders, along with significant advancements in peptide synthesis and therapeutic technologies.

Key Drivers Enabling the Growth of the Peptide Therapeutics CDMO Market

Main key factors fostering the growth of the peptide therapeutics CDMO market include the rising demand for peptide-based treatments for chronic diseases, increased outsourcing by biopharmaceutical firms to leverage specialized expertise and reduce costs, and major advancements in peptide synthesis technologies. Furthermore, substantial investments in peptide research and development contribute to a robust pipeline of novel candidates. The expanding clinical applications of peptides, particularly in areas such as metabolic disorders, oncology, and personalized medicine, further increase the necessity for specialized contract manufacturing services.

Segment Insights

• By synthesis method, solid-phase peptide synthesis (SPPS) dominated the market because of its efficiency, scalability, and ability to produce high-purity peptides, enabling large quantities of reagents to drive reactions to completion.
• By service type, the API development & manufacturing segment led the market. Peptide-based drugs are highly effective for chronic diseases like cancer, and CDMOs provide the necessary specialized expertise, advanced technology, and cost-effective solutions.
• By peptide type, the generic & innovative peptides segment held a dominant position in the market, as innovative peptides benefit from extensive research and development (R&D), new therapeutic approaches, and substantial investment.
• By application area, the oncology and diabetes segments accounted for the largest market shares due to the high and increasing prevalence of these chronic conditions and the unique therapeutic benefits that peptides offer for these diseases.
• By scale of operations, the commercial-scale manufacturing segment dominated the market, as it supports the growing demand for peptide-based drugs, enabling efficient production of approved drugs to meet large market needs.
• By end-user type, large pharmaceutical companies led the market due to their significant investments in peptide drug development for chronic diseases such as diabetes and cancer. They leverage the precision targeting and minimal side effects associated with peptides.

Regional Insights

North America led the peptide therapeutics CDMO market, thanks to its robust biopharmaceutical ecosystem, extensive R&D investment, advanced technological infrastructure, and strong regulatory frameworks. The presence of major pharmaceutical companies and a thriving biotech landscape fosters innovation and creates demand for specialized CDMO services, allowing these organizations to meet evolving market needs and optimize complex manufacturing processes.

Asia Pacific region is the fastest-growing in the market, driven by rapid industrialization, a growing middle-class population, significant investments in infrastructure and manufacturing, a strong presence of contract manufacturing organizations, and government support for biopharmaceutical R&D. Key countries driving this growth include China, India, and Japan. A rapidly expanding middle-class population leads to increased healthcare spending and a rising demand for new and diverse treatments.

Peptide Therapeutics CDMO  Market Coverage

Recent Development

• In March 2025, Shilpa Medicare launched its new full-service hybrid CDMO at the DCAT 2025 event. This newly formed CDMO will serve both small and large molecule customers, including peptides, with oncology being a particular area of focus. Shilpa's hybrid CDMO model also features commercially ready "off-the-shelf" novel formulations available for exclusive B2B licensing. (Source: https://www.shilpabio.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6786

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344